Clinical Research Unit​

The Clinical Research Unit (CRU) is a core facility of the Aga Khan University Cancer Centre- Experimental Therapeutics program and has established in line with AKU’s clinical and translational research agenda. 

The CRU supports high quality human subjects research and research processes to facilitate timely, ICH-GCP compliant clinical research studies from conception through to completion.



The CRU occupies a newly renovated space located on the 9th Floor of the Doctor’s Park Building, adjacent to the Aga Khan University Hospital, Nairobi and Aga Khan University Centre along 3rd Parklands Avenue Nairobi. Read More​



The CRU functions as a “one stop” operation and provides all the resources, support services and trained personnel to facilitate the conduct of ICH-GCP/FDA compliant clinical trials. ​Read More​

​​Frequently Asked Questions​​​​​​​​​​

What is a clinical trial? Do I have to pay to be in a clinical trial. All your ​questions answered. ​Read More​

Message from the Director​

It gives me great pleasure to announce the establishment of the Clinical Research Unit, a first at Aga Khan University in Nairobi. The Clinical Research Unit (CRU) is a core facility of the Experimental Therapeutics Program of Aga Khan University, Nairobi Cancer Centre. The CRU will be dedicated to cancer clinical trials and will set the stage for training of clinical investigators across the AKU East Africa campuses. Through our offering of novel clinical trials, we aim to attract patients from across East Africa and Sub-Sahara Africa. 

The motto of the CRU is "A drug called -TUMAINI". Tumaini is a Swahili word that means Hope. The AKU, N CRU is dedicated to providing hope to cancer patients. We are committed to ensure that they receive the best of oncologic care in the context of being part of a clinical trial.  Our clinical trials program is dedicated to the study of novel therapies in the management of cancer. The study of novel agents is something that has, to-date, been lacking in sub Saharan Africa (SSA).  The basis for this aspiration is that the outcome (response) and effect (toxicity) of anti-cancer agents may be variable in genetically disparate populations given the impact of pharmacogenomics on drug metabolism and kinetics, both of which can potentially impact response and toxicity.  There are numerous examples that underscore this premise and inform our desire to study novel anti-cancer agents in the SSA context in order to determine their utility in the African host.

We would like our patients and referring colleagues to see the Clinical Research Program as a close-to-home destination for access to novel therapeutic options. 

Prof Mansoor Saleh,
Founding Director,
AKU Cancer Centre and Clinical Research Unit

​Kenyans encourage to volunteer for medical research

​Contact Us

​Doctors Park Building
9th Floor
3rd Parklands Avenue

Tel: +254 020 366 1097

P.O. Box 30270 – 00100
Nairobi, Kenya